Bellia V, Ferrara G, Cibella F, Cuttitta G, Visconti A, Insalaco G, Mirto M, Peralta G
Istituto di Pneumologia dell'Università, Palermo, Italy.
Postgrad Med J. 1988 Aug;64(754):583-6. doi: 10.1136/pgmj.64.754.583.
The effects of a new inhaled antimuscarinic drug, oxitropium bromide, and of a slow-release theophylline preparation upon nocturnal asthma were compared in a placebo-controlled double-blind study. Two samples were studied: 12 patients received oxitropium at 600 micrograms (6 subjects) or at 400 micrograms t.i.d. (6 subjects) whereas 11 received theophylline at 300 mg b.i.d. Morning dipping, assessed by the fall in peak flow overnight, was significantly reduced in the periods when either active drug was taken, whereas no difference was noticed during the placebo administration. No significant difference was noticed between results obtained with either active drug, as well as with either dosage of oxitropium. No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline. Oxitropium proves to be a valuable alternative to theophylline in nocturnal asthma, since it is equally potent, safer and does not require the titration of dosage.
在一项安慰剂对照的双盲研究中，比较了一种新型吸入性抗胆碱能药物氧托溴铵和一种缓释茶碱制剂对夜间哮喘的影响。研究了两个样本：12名患者接受600微克（6名受试者）或400微克每日三次（6名受试者）的氧托溴铵，而11名患者接受300毫克每日两次的茶碱。通过夜间峰流速下降评估的晨降现象，在服用任何一种活性药物期间均显著降低，而在服用安慰剂期间未观察到差异。两种活性药物以及氧托溴铵的两种剂量所获得的结果之间均未观察到显著差异。与三名报告在服用茶碱后出现恶心、呕吐和震颤的受试者相比，没有受试者报告氧托溴铵的副作用。在夜间哮喘治疗中，氧托溴铵被证明是茶碱的一种有价值的替代药物，因为它同样有效、更安全且不需要调整剂量。
